At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
acipimox +1 moredrug
Likely dose
acipimox 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
In Brief
A Phase 3 clinical trial evaluating acipimox and Placebo for Metabolic Syndrome. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedSep 2008
Primary CompletionDec 2017
Study CompletionDec 2017
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartApr 1, 2006
Primary CompletionDec 1, 2017
Study CompletionDec 30, 2017
TodayJul 2, 2026
Enrollment to primary: 11.7 yearsPosted 17.8 years ago
Interventions
acipimoxdrug
250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
Placebodrug
1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit